Advances in Lymphoma Molecular Diagnostics

Kos, Igor; Thurner, Lorenz; Bittenbring, Joerg Thomas; Christofyllakis, Konstantinos; Kaddu‐Mulindwa, Dominic

doi:10.3390/diagnostics11122174

Cited by 4 publications

(2 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, myeloid, lymphoid, and genome-wide mutations have been recognized using a large population in diffuse large B-cell lymphoma. These data sets, as a whole, describe the complicated fitness for genetic alterations that give rise to lymphomagenesis and highlight the role of this clinical setting in offering a framework for targeted therapy and prognostication (Kos et al, 2021). Summary: Genetic biomarkers related to lymphomagenesis take on different regulatory cleavages, and such a role depends on the clinical outcomes of the patients.…”

Section: Genetic Biomarkersmentioning

confidence: 99%

Predictive biomarkers in lymphoma: a systematic research review

Lima Cajas,

Panchi Espin,

Lalama Rueda

et al. 2024

IBEROJHR

View full text Add to dashboard Cite

Lymphoma is a diverse group of blood cancers originating in the lymphatic system, with varying clinical presentations and prognoses. Identifying and utilizing predictive biomarkers in lymphoma can significantly impact the management and outcome of patients. For instance, the presence of the BCL2 gene rearrangement in follicular lymphoma is associated with a poorer prognosis, while the expression of the CD20 protein in diffuse large B-cell lymphoma is a predictor of response to rituximab. These biomarkers are molecular or cellular indicators that can help forecast disease progression, therapeutic response, and patient prognosis. This abstract provides an overview of the current landscape of predictive biomarkers in lymphoma, focusing on their role which can help physicians to build personalized treatment strategies. We explore key types of biomarkers, including genetic mutations, protein expressions, and cellular markers, that have shown potential in predicting treatment response and survival outcomes across different lymphoma subtypes. Furthermore, we delve into recent advancements in biomarker discovery through high-throughput technologies such as next-generation sequencing and their strategic integration into clinical practice. The use of predictive biomarkers not only enhances the precision of treatment regimens but also contributes to better risk stratification and patient monitoring. The future of this field involves the refinement of biomarker panels for improved predictive accuracy and the exploration of novel targets for therapy. The strategic application of predictive biomarkers in lymphoma presents promising opportunities for optimizing patient care and advancing precision medicine in hematological malignancies.

show abstract

Section: Genetic Biomarkersmentioning

confidence: 99%

Predictive biomarkers in lymphoma: a systematic research review

Lima Cajas,

Panchi Espin,

Lalama Rueda

et al. 2024

IBEROJHR

View full text Add to dashboard Cite

show abstract

“…These classifications allow for more precise diagnosis and treatment selection, ultimately improving patient outcomes. 3 , 5 , 6 , 7 , 8 …”

Section: Introductionmentioning

confidence: 99%

Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma

Bønløkke,

Fenger-Eriksen,

Ommen

et al. 2023

Blood Advances

View full text Add to dashboard Cite

Thrombosis and bleeding are significant contributors to morbidity and mortality in patients with hematological cancer, and the impact of altered fibrinolysis on bleeding and thrombosis risk is poorly understood. In this prospective cohort study, we investigated the dynamics of fibrinolysis in hematological cancer patients. Fibrinolysis was investigated prior to treatment and three months after treatment initiation. A dynamic clot formation and lysis assay was performed beyond the measurement of plasminogen activator inhibitor 1, tissue- and urokinase-type plasminogen activators (tPA and uPA), plasmin-antiplasmin complexes (PAP), α-2-antiplasmin activity, and plasminogen activity. Clot initiation, clot propagation, and clot strength were assessed using thromboelastometry (ROTEM®). A total of 79 patients were enrolled. Lymphoma patients displayed impaired fibrinolysis with prolonged 50% clot lysis time compared to healthy controls (p = 0.048). They also displayed decreased clot strength at follow-up compared to at diagnosisp (p = 0.001). A patient with amyloid-light-chain amyloidosis having overt bleeding at diagnosis displayed hyperfibrinolysis, indicated by a reduced 50% clot lysis time, α-2-antiplasmin activity, and plasminogen activity and elevated tPA and uPA. A patient with acute promyelocytic leukemia also displayed marked hyperfibrinolysis with very high PAP indicating extreme plasmin generation, and clot formation was not measurable probably due to the extremely fast fibrinolysis. Fibrinolysis returned to normal after treatment in both patients. In conclusion, lymphoma patients showed signs of impaired fibrinolysis and increased clot strength, whereas hyperfibrinolysis was seen in patients with acute promyelocytic leukemia and light-chain amyloidosis. Thus, investigating fibrinolysis in hematological cancer patients could have diagnostic value.

show abstract

Updates on Molecular Pathogenesis of Non-Hodgkin’s Lymphoma

Abolhassani

2023

Interdisciplinary Cancer Research

View full text Add to dashboard Cite

Advances in Lymphoma Molecular Diagnostics

Cited by 4 publications

References 130 publications

Predictive biomarkers in lymphoma: a systematic research review

Predictive biomarkers in lymphoma: a systematic research review

Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma

Updates on Molecular Pathogenesis of Non-Hodgkin’s Lymphoma

Contact Info

Product

Resources

About